Form 4: Intellia Therapeutics EVP Birgit Schultes Reports Stock and Option Transactions

EVP and Chief Scientific Officer of Intellia Therapeutics, Birgit Schultes, reports acquisition of restricted stock units and stock options.

Summary

• On March 1, 2025, Birgit C Schultes, EVP and Chief Scientific Officer of Intellia Therapeutics, acquired 37,600 shares of common stock and 53,714 stock options.
• The stock acquisition was a grant of restricted stock units, each representing a contingent right to receive one share of Intellia common stock.
• The stock options, with an exercise price of $10.09, were granted on March 1, 2025, and vest in installments, with 33% vesting on January 1, 2026, and the remaining 67% vesting monthly over the following 24 months.
• Following these transactions, Schultes directly owns 105,215 shares of Intellia common stock and 53,714 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine executive compensation. The acquisition of stock and options by an executive is generally viewed as a positive sign, but it's a standard practice.

Positives

• The acquisition of stock and options by a key executive could be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in biotech companies like Intellia Therapeutics.
• Comparable companies such as CRISPR Therapeutics and Editas Medicine also utilize stock options and RSUs as part of their executive compensation packages to align management interests with shareholder value.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder sentiment, as they indicate executive confidence in the company.

Key Dates